UBS downgraded Nanobiotix (NBTX) to Neutral from Buy with a price target of $3.50, down from $12, as a new analyst assumed coverage of the stock. The next major catalyst is more than 12 months away and the firm sees a near-term financing overhang limiting potential upside, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX: